Carbaglu — CareFirst (Caremark)
Methylmalonic acidemia
Initial criteria
- Member has a diagnosis of methylmalonic acidemia
Reauthorization criteria
- Member is experiencing benefit from therapy as evidenced by disease stability or disease improvement
Approval duration
12 months